The Food and Drug Administration on Thursday approved Bayer HealthCare Pharmaceutical's drug Stivarga to treat liver cancer.
The FDA first approved Stivarga in September 2012 to treat colorectal cancer patients who don't respond to initial treatments. Now, the drug can also be used as a second-line treatment for hepatocellular carcinoma, the most common type of liver cancer.
Stivarga's expanded approval marks the first new treatment for liver cancer in nearly a decade, according to the FDA.
More articles on supply chain:
Corporate Whistleblower Center encourages pharma employees to report unsanitary drug plant conditions
7 must-reads for supply chain leaders this week
Dem. Senators pen letter to Dr. Scott Gottlieb on FDA hiring freeze